

Baxter International Inc.
Key Product Line Sales -- US/International
Period Ending December 31, 2005
(unaudited)

(\$ in millions)	Q4 2005			Q4 2004			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$168	\$226	\$394	\$173	\$203	\$376	(3%)	11%	5%
Plasma Proteins ¹	113	143	\$256	118	160	278	(4%)	(11%)	(8%)
Antibody Therapy	103	44	\$147	46	38	84	124%	16%	75%
Transfusion Therapies	67	73	\$140	76	74	150	(12%)	(1%)	(7%)
Other ²	28	45	\$73	35	29	64	(20%)	55%	14%
Total BioScience	\$479	\$531	\$1,010	\$448	\$504	\$952	7%	5%	6%
Medication Delivery									
IV Therapies ³	\$109	\$207	\$316	\$104	\$205	\$309	5%	1%	2%
Drug Delivery	128	68	196	186	66	252	(31%)	3%	(22%)
Infusion Systems	123	71	194	184	75	259	(33%)	(5%)	(25%)
Anesthesia	166	83	249	214	74	288	(22%)	12%	(14%)
Other ⁴	6	11	17	6	15	21	-%	(27%)	(19%)
Total Medication Delivery ⁵	\$532	\$440	\$972	\$694	\$435	\$1,129	(23%)	1%	(14%)
Renal									
PD Therapy	\$62	\$332	\$394	\$65	\$317	\$382	(5%)	5%	3%
HD Therapy	31	78	109	35	99	134	(11%)	(21%)	(19%)
Other	3	3	6	3	1	4	-%	200%	50%
Total Renal	\$96	\$413	\$509	\$103	\$417	\$520	(7%)	(1%)	(2%)
TOTAL BAXTER	\$1,107	\$1,384	\$2,491	\$1,245	\$1,356	\$2,601	(11%)	2%	(4%)

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes other hospital-distributed products.

⁵ Sales of oncology products, which were previously included in Other, are now reported in Drug Delivery, Infusion Systems or Anesthesia, depending on the product. All prior year sales data has been reclassified to reflect this change.